Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 12/03/25
Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3Business Wire • 11/19/25
Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 TranscriptSeeking Alpha • 11/11/25
Vertex Pharmaceuticals Incorporated (VRTX) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio TranscriptSeeking Alpha • 11/09/25
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney WeekBusiness Wire • 11/08/25
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?Zacks Investment Research • 11/05/25
Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy"Seeking Alpha • 11/04/25
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top EstimatesZacks Investment Research • 11/04/25
Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 11/04/25
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance BookInvestors Business Daily • 11/03/25